1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 SX-PCK9 1.2.3 O-304 1.2.4 K-312 1.2.5 BLSM-201 1.2.6 DCRPCSK-9 1.2.7 Others 1.3 Market by Application 1.3.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Cardiovascular Disease 1.3.3 Homozugous Familial Hyperchalesterolemia 1.3.4 Liver Disease 1.3.5 Metabolic Syndrome 1.3.6 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Perspective (2016-2027) 2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Growth Trends by Regions 2.2.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Historic Market Share by Regions (2016-2021) 2.2.3 Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Regions (2022-2027) 2.3 Proprotein Convertase Subtilisin/Kexin Type 9 Industry Dynamic 2.3.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Trends 2.3.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Drivers 2.3.3 Proprotein Convertase Subtilisin/Kexin Type 9 Market Challenges 2.3.4 Proprotein Convertase Subtilisin/Kexin Type 9 Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Revenue 3.1.1 Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Revenue (2016-2021) 3.1.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Players (2016-2021) 3.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue 3.4 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Concentration Ratio 3.4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue in 2020 3.5 Proprotein Convertase Subtilisin/Kexin Type 9 Key Players Head office and Area Served 3.6 Key Players Proprotein Convertase Subtilisin/Kexin Type 9 Product Solution and Service 3.7 Date of Enter into Proprotein Convertase Subtilisin/Kexin Type 9 Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Type 4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Historic Market Size by Type (2016-2021) 4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Type (2022-2027) 5 Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Application 5.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Historic Market Size by Application (2016-2021) 5.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027) 6.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type 6.2.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) 6.2.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) 6.2.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027) 6.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application 6.3.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) 6.3.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) 6.3.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027) 6.4 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country 6.4.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) 6.4.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027) 7.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type 7.2.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) 7.2.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) 7.2.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027) 7.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application 7.3.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) 7.3.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) 7.3.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027) 7.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country 7.4.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) 7.4.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027) 8.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type 8.2.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027) 8.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application 8.3.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027) 8.4 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region 8.4.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027) 9.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type 9.2.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) 9.2.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) 9.2.3 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027) 9.3 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application 9.3.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) 9.3.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) 9.3.3 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027) 9.4 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country 9.4.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) 9.4.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027) 10.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type 10.2.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027) 10.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application 10.3.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027) 10.4 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country 10.4.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 AFFiRiS AG 11.1.1 AFFiRiS AG Company Details 11.1.2 AFFiRiS AG Business Overview 11.1.3 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.1.4 AFFiRiS AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.1.5 AFFiRiS AG Recent Development 11.2 Betagenon AB 11.2.1 Betagenon AB Company Details 11.2.2 Betagenon AB Business Overview 11.2.3 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.2.4 Betagenon AB Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.2.5 Betagenon AB Recent Development 11.3 Bioleaders Corp 11.3.1 Bioleaders Corp Company Details 11.3.2 Bioleaders Corp Business Overview 11.3.3 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.3.4 Bioleaders Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.3.5 Bioleaders Corp Recent Development 11.4 BioLingus AG 11.4.1 BioLingus AG Company Details 11.4.2 BioLingus AG Business Overview 11.4.3 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.4.4 BioLingus AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.4.5 BioLingus AG Recent Development 11.5 Catabasis Pharmaceuticals Inc 11.5.1 Catabasis Pharmaceuticals Inc Company Details 11.5.2 Catabasis Pharmaceuticals Inc Business Overview 11.5.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.5.4 Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.5.5 Catabasis Pharmaceuticals Inc Recent Development 11.6 Dicerna Pharmaceuticals Inc 11.6.1 Dicerna Pharmaceuticals Inc Company Details 11.6.2 Dicerna Pharmaceuticals Inc Business Overview 11.6.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.6.4 Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.6.5 Dicerna Pharmaceuticals Inc Recent Development 11.7 Eli Lilly and Co 11.7.1 Eli Lilly and Co Company Details 11.7.2 Eli Lilly and Co Business Overview 11.7.3 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.7.4 Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.7.5 Eli Lilly and Co Recent Development 11.8 Ensemble Therapeutics Corp 11.8.1 Ensemble Therapeutics Corp Company Details 11.8.2 Ensemble Therapeutics Corp Business Overview 11.8.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.8.4 Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.8.5 Ensemble Therapeutics Corp Recent Development 11.9 Kowa Co Ltd 11.9.1 Kowa Co Ltd Company Details 11.9.2 Kowa Co Ltd Business Overview 11.9.3 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.9.4 Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.9.5 Kowa Co Ltd Recent Development 11.10 Novartis AG 11.10.1 Novartis AG Company Details 11.10.2 Novartis AG Business Overview 11.10.3 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.10.4 Novartis AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.10.5 Novartis AG Recent Development 11.11 Pfizer Inc 11.11.1 Pfizer Inc Company Details 11.11.2 Pfizer Inc Business Overview 11.11.3 Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.11.4 Pfizer Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.11.5 Pfizer Inc Recent Development 11.12 Regeneron Pharmaceuticals Inc 11.12.1 Regeneron Pharmaceuticals Inc Company Details 11.12.2 Regeneron Pharmaceuticals Inc Business Overview 11.12.3 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.12.4 Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.12.5 Regeneron Pharmaceuticals Inc Recent Development 11.13 Serometrix LLC 11.13.1 Serometrix LLC Company Details 11.13.2 Serometrix LLC Business Overview 11.13.3 Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.13.4 Serometrix LLC Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.13.5 Serometrix LLC Recent Development 11.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 11.14.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Details 11.14.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview 11.14.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.14.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.14.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development 11.15 The Medicines Company 11.15.1 The Medicines Company Company Details 11.15.2 The Medicines Company Business Overview 11.15.3 The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Introduction 11.15.4 The Medicines Company Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) 11.15.5 The Medicines Company Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of SX-PCK9 Table 3. Key Players of O-304 Table 4. Key Players of K-312 Table 5. Key Players of BLSM-201 Table 6. Key Players of DCRPCSK-9 Table 7. Key Players of Others Table 8. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Regions (2016-2021) & (US$ Million) Table 11. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions (2016-2021) Table 12. Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 13. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions (2022-2027) Table 14. Proprotein Convertase Subtilisin/Kexin Type 9 Market Trends Table 15. Proprotein Convertase Subtilisin/Kexin Type 9 Market Drivers Table 16. Proprotein Convertase Subtilisin/Kexin Type 9 Market Challenges Table 17. Proprotein Convertase Subtilisin/Kexin Type 9 Market Restraints Table 18. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Players (2016-2021) & (US$ Million) Table 19. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Players (2016-2021) Table 20. Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 as of 2020) Table 21. Ranking of Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Companies by Revenue (US$ Million) in 2020 Table 22. Global 5 Largest Players Market Share by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (CR5 and HHI) & (2016-2021) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Proprotein Convertase Subtilisin/Kexin Type 9 Product Solution and Service Table 25. Date of Enter into Proprotein Convertase Subtilisin/Kexin Type 9 Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million) Table 28. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2016-2021) Table 29. Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Type (2022-2027) (US$ Million) Table 30. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2022-2027) & (US$ Million) Table 31. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Share by Application (2016-2021) & (US$ Million) Table 32. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Application (2016-2021) Table 33. Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Application (2022-2027) (US$ Million) Table 34. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Application (2022-2027) & (US$ Million) Table 35. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million) Table 36. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million) Table 37. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million) Table 38. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million) Table 39. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million) Table 40. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million) Table 41. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million) Table 42. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million) Table 43. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million) Table 44. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million) Table 45. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million) Table 46. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million) Table 47. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million) Table 48. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million) Table 49. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million) Table 50. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million) Table 51. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2016-2021) & (US$ Million) Table 52. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2022-2027) & (US$ Million) Table 53. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million) Table 54. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million) Table 55. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million) Table 56. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million) Table 57. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million) Table 58. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million) Table 59. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million) Table 60. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million) Table 61. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million) Table 62. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million) Table 63. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million) Table 64. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million) Table 65. AFFiRiS AG Company Details Table 66. AFFiRiS AG Business Overview Table 67. AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 68. AFFiRiS AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 69. AFFiRiS AG Recent Development Table 70. Betagenon AB Company Details Table 71. Betagenon AB Business Overview Table 72. Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 73. Betagenon AB Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 74. Betagenon AB Recent Development Table 75. Bioleaders Corp Company Details Table 76. Bioleaders Corp Business Overview Table 77. Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 78. Bioleaders Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 79. Bioleaders Corp Recent Development Table 80. BioLingus AG Company Details Table 81. BioLingus AG Business Overview Table 82. BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 83. BioLingus AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 84. BioLingus AG Recent Development Table 85. Catabasis Pharmaceuticals Inc Company Details Table 86. Catabasis Pharmaceuticals Inc Business Overview Table 87. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 88. Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 89. Catabasis Pharmaceuticals Inc Recent Development Table 90. Dicerna Pharmaceuticals Inc Company Details Table 91. Dicerna Pharmaceuticals Inc Business Overview Table 92. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 93. Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 94. Dicerna Pharmaceuticals Inc Recent Development Table 95. Eli Lilly and Co Company Details Table 96. Eli Lilly and Co Business Overview Table 97. Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 98. Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 99. Eli Lilly and Co Recent Development Table 100. Ensemble Therapeutics Corp Company Details Table 101. Ensemble Therapeutics Corp Business Overview Table 102. Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 103. Ensemble Therapeutics Corp Recent Development Table 104. Kowa Co Ltd Company Details Table 105. Kowa Co Ltd Business Overview Table 106. Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 107. Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 108. Kowa Co Ltd Recent Development Table 109. Novartis AG Company Details Table 110. Novartis AG Business Overview Table 111. Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 112. Novartis AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 113. Novartis AG Recent Development Table 114. Pfizer Inc Company Details Table 115. Pfizer Inc Business Overview Table 116. Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 117. Pfizer Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 118. Pfizer Inc Recent Development Table 119. Regeneron Pharmaceuticals Inc Company Details Table 120. Regeneron Pharmaceuticals Inc Business Overview Table 121. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 122. Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 123. Regeneron Pharmaceuticals Inc Recent Development Table 124. Serometrix LLC Company Details Table 125. Serometrix LLC Business Overview Table 126. Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 127. Serometrix LLC Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 128. Serometrix LLC Recent Development Table 129. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Details Table 130. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview Table 131. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 132. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 133. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development Table 134. The Medicines Company Company Details Table 135. The Medicines Company Business Overview Table 136. The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Product Table 137. The Medicines Company Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million) Table 138. The Medicines Company Recent Development Table 139. Research Programs/Design for This Report Table 140. Key Data Information from Secondary Sources Table 141. Key Data Information from Primary Sources List of Figures Figure 1. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type: 2020 VS 2027 Figure 2. SX-PCK9 Features Figure 3. O-304 Features Figure 4. K-312 Features Figure 5. BLSM-201 Features Figure 6. DCRPCSK-9 Features Figure 7. Others Features Figure 8. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application: 2020 VS 2027 Figure 9. Cardiovascular Disease Case Studies Figure 10. Homozugous Familial Hyperchalesterolemia Case Studies Figure 11. Liver Disease Case Studies Figure 12. Metabolic Syndrome Case Studies Figure 13. Others Case Studies Figure 14. Proprotein Convertase Subtilisin/Kexin Type 9 Report Years Considered Figure 15. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 16. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 17. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions: 2020 VS 2027 Figure 18. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions (2022-2027) Figure 19. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Players in 2020 Figure 20. Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 as of 2020 Figure 21. The Top 10 and 5 Players Market Share by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue in 2020 Figure 22. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2016-2021) Figure 23. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2022-2027) Figure 24. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027) Figure 26. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027) Figure 27. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027) Figure 28. United States Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Canada Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027) Figure 32. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027) Figure 33. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027) Figure 34. Germany Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. France Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. U.K. Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Italy Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Russia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Nordic Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027) Figure 42. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027) Figure 43. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Region (2016-2027) Figure 44. China Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Japan Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. South Korea Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. India Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Australia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027) Figure 52. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027) Figure 53. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027) Figure 54. Mexico Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Brazil Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027) Figure 58. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027) Figure 59. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027) Figure 60. Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. Saudi Arabia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. UAE Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million) Figure 63. AFFiRiS AG Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 64. Betagenon AB Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 65. Bioleaders Corp Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 66. BioLingus AG Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 67. Catabasis Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 68. Dicerna Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 69. Eli Lilly and Co Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 70. Ensemble Therapeutics Corp Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 71. Kowa Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 72. Novartis AG Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 73. Pfizer Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 74. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 75. Serometrix LLC Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 76. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 77. The Medicines Company Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) Figure 78. Bottom-up and Top-down Approaches for This Report Figure 79. Data Triangulation Figure 80. Key Executives Interviewed

AFFiRiS AG Betagenon AB Bioleaders Corp BioLingus AG Catabasis Pharmaceuticals Inc Dicerna Pharmaceuticals Inc Eli Lilly and Co Ensemble Therapeutics Corp Kowa Co Ltd Novartis AG Pfizer Inc Regeneron Pharmaceuticals Inc Serometrix LLC Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd The Medicines Company